Medicine 3.0: The Future of Healthcare Is Here

In his influential book Outlive, Dr Peter Attia outlines a bold new vision for the future of healthcare. One that moves decisively away from the reactive, disease-focused paradigm of the past and toward a new model he calls Medicine 3.0. This vision is grounded in prevention, individualised data, early risk identification, and a commitment to extending healthspan, not just lifespan.

Dr Attia's framework focuses on addressing what he calls the "Four Horsemen of chronic disease": cardiovascular disease, cancer, neurodegenerative disease, and type 2 diabetes, before they take hold. He argues that early, individualised metrics are essential for improving not just lifespan, but healthspan: the number of years lived in optimal health. These concepts form the philosophical backbone of Medicine 3.0, and they're also at the heart of CardiAction's mission.

CardiAction was built from the ground up with this shift in mind. Its algorithm, built on over a decade of research by Dr Paul Beaver and validated through clinical work with Dr John Cook, mirrors many of the principles that Dr Attia and other leading thinkers are now championing. Increasingly, global leaders in healthcare are converging on the same insight: the current system is failing to prevent chronic disease, and we need new tools and frameworks to change the trajectory.

From Medicine 2.0 to Medicine 3.0

Dr Attia describes Medicine 2.0 as the status quo. A reactive, guideline-driven system built to treat disease after it has already developed. It is a model based on averages, not individuals, or even the difference between men and women, and one that too often waits for failure before intervening. Cardiovascular disease, type 2 diabetes, and metabolic dysfunction are all largely preventable, yet the system remains focused on treatment over prevention.

Medicine 3.0, in contrast, is personalised, data-rich, and proactive. It embraces early indicators of risk, advanced diagnostics and screening, and a broader definition of "health." It recognises that our biggest killers (heart disease, cancer, neurodegeneration, and type 2 diabetes) often begin years or decades before symptoms emerge. Prevention must happen earlier, be more targeted, and be driven by technology and evidence, not just intuition.

This is precisely the worldview that underpins CardiAction.

CardiAction: A Multi-Biometric Dynamic Algorithm for a New Era of Prevention

The CardiAction dynamic algorithm does not rely on outdated population averages. It integrates a range of key biometric inputs to assess an individual's risk of a major cardiovascular event well before symptoms appear. These inputs include physiological measurements such as blood pressure, heart rate variability, arterial stiffness indicators, and unique telemetry derived from pulse wave analysis (PWA), among others.

PWA is an important part of the CardiAction approach, but it is not the whole story. Rather, it contributes valuable and unique telemetry to a broader set of biometric data points that feed into CardiAction's algorithm. These inputs are analysed in aggregate to generate a personalised Cardiovascular Risk Score and inform recommendations that reflect an individual's current physiological state.

This approach avoids the need for invasive blood tests or complex diagnostics. It offers a fast, accessible, and scalable way to detect early warning signs of cardiovascular risk, empowering individuals to act sooner. It is not just a new tool. It represents a new philosophy of care.

CardiAction Screening Pathways

CardiAction is delivered through two screening pathways, designed to work together as a continuum:

Traditional cardiovascular risk models like the Framingham Risk Score rely on retrospective population averages and a limited set of factors such as age, cholesterol levels, and smoking status. Developed almost 80 years ago, these models often miss key real-time indicators and fail to account for meaningful differences between individuals, including gender. CardiAction moves beyond these static assessments by integrating dynamic, real-time biometric telemetry such as arterial stiffness and central blood pressure. This provides a more precise, sensitive, and personalised window into vascular health.

CardiAction has already been independently validated in a report by Griffith University, which confirmed that its results are a reliable proxy for more complex, invasive, and expensive cardiovascular assessments.

Together, CardiAction PreScreen and ProScreen provide a layered, population-to-personal pathway that delivers on the promise of Medicine 3.0: proactive, data-rich, individualised, and designed to intervene before symptoms appear.

Parallel Paths: Dr Paul Beaver, Dr John Cook, and Dr Peter Attia

While Dr Attia came to these conclusions through his clinical work and synthesis of longevity science, our own researchers, Dr Paul Beaver and Dr John Cook, arrived at the same destination through a different path: primary research and the development of a multi-biometric dynamic algorithm for early cardiovascular event risk assessment.

Over the past 15 years, their work has consistently argued that cardiovascular risk can and should be detected earlier by harnessing biometric telemetry that goes beyond conventional population-based models. Unlike traditional systems that rely on invasive blood tests, expensive imaging, or narrow risk factors such as age, cholesterol, and smoking status, the CardiAction approach captures dynamic, real-time physiological signals like arterial stiffness, central blood pressure, and pulse wave characteristics.

Like Dr Attia, they recognised that the prevailing system is reactive, heavily dependent on retrospective averages developed decades ago, and often blind to the early warning signs present in individuals who appear healthy by conventional standards.

Just as Attia makes the case that metabolic health is foundational and widely misunderstood, Beaver and Cook's work demonstrates that dynamic vascular and biometric signals, when analysed in the right context, can provide an accurate early warning system for cardiovascular dysfunction. The convergence is not coincidental. It reflects a broader shift in understanding, now supported by a growing international community.

Why the World Is Catching Up

CardiAction is not alone in this view. Across the world, forward-thinking practitioners, researchers, and healthcare systems are embracing this shift:

• The NHS in the UK is expanding preventative health screening in pharmacies and community settings.
• US-based healthtech platforms like Levels and InsideTracker are pushing personalised metabolic data to consumers.
• Longevity-focused clinics and startups are emerging globally with a focus on health optimisation.
• Australia's Heart Foundation and primary care networks are ramping up risk detection efforts outside traditional GP consults.

This wave of innovation points in one direction. A healthcare system that no longer waits for disease to strike, but seeks to intervene early, often, and smartly.

CardiAction is proud to be part of this leading global movement.

The Shift Is Not Coming. It Is Already Here.

"Our current medical system is well designed to treat the ill. It is poorly designed to prevent people from becoming ill in the first place."

Dr Peter Attia, Outlive

At CardiAction, we could not agree more. That is why we have built our technology and philosophy on the principles of Medicine 3.0, years before the term was coined and the team at CardiAction heard of Dr Attia.

With the international validation of these ideas by leaders like Dr Attia, Dr Paul Beaver and Dr John Cook, along with real-world results emerging from our partnerships in New Zealand and Australia, it is clear that CardiAction represents not just a novel tool, but a necessary shift in how we think about cardiovascular health.

The world is changing. The system must change with it. And CardiAction is ready.